GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Salarius Pharmaceuticals Inc (NAS:SLRX) » Definitions » Gross Margin %

Salarius Pharmaceuticals (Salarius Pharmaceuticals) Gross Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Salarius Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Salarius Pharmaceuticals's Gross Profit for the three months ended in Dec. 2023 was $0.00 Mil. Salarius Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Salarius Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Salarius Pharmaceuticals's Gross Margin % or its related term are showing as below:


During the past 10 years, the highest Gross Margin % of Salarius Pharmaceuticals was 60.28%. The lowest was 34.42%. And the median was 48.57%.

SLRX's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.4
* Ranked among companies with meaningful Gross Margin % only.

Salarius Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Salarius Pharmaceuticals was 0.00% per year.


Salarius Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Salarius Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Salarius Pharmaceuticals Gross Margin % Chart

Salarius Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Salarius Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Salarius Pharmaceuticals's Gross Margin %

For the Biotechnology subindustry, Salarius Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Salarius Pharmaceuticals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Salarius Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Salarius Pharmaceuticals's Gross Margin % falls into.



Salarius Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Salarius Pharmaceuticals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

Salarius Pharmaceuticals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Salarius Pharmaceuticals  (NAS:SLRX) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Salarius Pharmaceuticals had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Salarius Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Salarius Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Salarius Pharmaceuticals (Salarius Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The Company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Executives
Tess Burleson director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan I Lieber director C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
William K. Mcvicar director C/O INOTEK PHARMACEUTICALS CORPORATION, 131 HARTWELL AVENUE, SUITE 105, LEXINGTON MA 02421
Arnold C Hanish director 201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Mark J Rosenblum officer: Exec VP Finance, Interim CFO 3990 SPRING VALLEY ROAD, APT. 1218, DALLAS TX 75244
David J. Arthur director, officer: Chief Executive Officer 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Scott Jordan officer: Chief Financial Officer 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Mccreedy Bruce J Jr. director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Jonathan P Northrup director 2450 HOLCOME BLVD., SUITE J-608, HOUSTON TX 77021
Pao-yu Chuang officer: Controller 2450 HOLCOMBE BLVD., SUITE J-608, HOUSTON TX 77021
Paul Lammers director 2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Boston Foundation, Inc. 10 percent owner 75 ARLINGTON STREET, BOSTON MA 02116
Christoph H Westphal 10 percent owner C/O ALNYLAM PHARMACEUTICALS, INC, 300 THIRD STREET, CAMBRIDGE MA 02142
Longwood Fund Ii, L.p. 10 percent owner 800 BOYLSTON STREET, SUITE 1555, BOSTON MA 02199
Roger D Tung director 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421

Salarius Pharmaceuticals (Salarius Pharmaceuticals) Headlines

From GuruFocus

Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split

By Value_Insider Value_Insider 10-14-2022